CD200

Across TCGA pan-cancer cohorts, CD200 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD200 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CD200 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD200 expression acts as an unfavorable survival marker.

LUSC, BLCA, and SARC are the cancer types where CD200 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.140	0.743	.001	30	view →
BLCA	DFS	Median	III,IV	0.121	0.548	.005	18	view →
SARC	OS	Median	All	0.022	0.861	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD200–LUSC (OS)

Open the LUSC breakdown →